



Docket No: 61254 CON (50586)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mitsunori Ono, *et al.*
Application No.: 10/656,360-Conf.# 7835 Group No.: 1624
Filed: September 5, 2003 Examiner: V. Balasubramanian
For: *TRIAZINE COMPOUNDS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

See added only

CERTIFICATE OF EXPRESS MAIL

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee," Express Mail Label No. EV437821946US addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on December 20, 2004.

By: *[Signature]*
Safiya Jarvis

RESPONSE

Dear Sir:

This is a response to the non-final Office Action mailed from the Patent and Trademark Office on July 19, 2004 (the "Action"). A two month extension of time is concurrently filed herewith. Please amend the above-identified U.S. patent application as follows (total of 16 pages):

Amendments to the Claims begins on page 2 of this paper.

Remarks begin on page 12 of this paper.

12/28/2004 WABDELRI 00000100 041105 10656360
01 FC:2202 775.00 DA

01/07/2005 TSUGGS 00000001 041105 10656360
01 FC:2202 50.00 DA

BOS2_468661_1/DKIM

12/28/2004 WABDELRI-00000099 041105 10656360
01 FC:2202 775.00 DA

MS, diabetes mellitus, psoriasis, and sepsis. Applicants therefore submit that the use of their instant triazine compounds, in view of the knowledge of the results observed using the above-mentioned treatments to lower TNF- α and IL-12 levels, satisfy the enablement requirement of 35 U.S.C. §112 for treating IL-12 overproduction related disorders. Applicants respectfully request withdrawal of this rejection.


CONCLUSION

In view of the above, reconsideration and withdrawal of all rejections and allowance of the application with claims 47 and 49-100 are respectfully solicited. Accordingly, the Examiner is respectfully requested to pass this application to issue. Should any of the claims not be found to be allowable, the Examiner is requested to telephone Applicants' undersigned representative at the number below. Applicants thank the Examiner in advance for this courtesy.

The Director is hereby authorized to charge or credit any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 50586-61254 CON.

Respectfully submitted,

Date: December 20, 2004

By 
Jeffrey D. Hsi
Registration No.: 40,024
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205
Phone (617) 439-4444
Fax: (617) 439-4170

Customer No. 21874